News
CYCC
--
0.00%
--
Hedge Funds Have Never Been This Bullish On Cyclacel Pharmaceuticals Inc (CYCC)
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of June 30th. The r...
Insider Monkey · 10/04 13:00
Cyclacel Pharmaceuticals Presenting at Three Conferences in September
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three investor confere...
GlobeNewswire · 09/08 11:00
BRIEF-Cyclacel Pharmaceuticals Inc - May Offer, Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $50 Million From Time To Time
reuters.com · 08/12 21:38
BRIEF-Cyclacel Pharmaceuticals Reports Q2 Financial Results
reuters.com · 08/11 21:07
Cyclacel Pharmaceuticals Q2 EPS $(0.56) Misses $(0.50) Estimate
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.50) by 12 percent. This is a 3.45 percent increase over losses of $(0.58) per share
Benzinga · 08/11 20:50
-- Earnings Flash (CYCC) CYCLACEL Reports Q2 Loss $-0.56, vs. Street Est of $-0.47
MT Newswires · 08/11 16:19
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update
Cyclacel will also participate in the BTIG Virtual Biotechnology ConferenceBERKELEY HEIGHTS, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company deve...
GlobeNewswire · 08/03 11:00
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12)
Benzinga · 07/13 12:05
Dosing underway in Cyclacel Pharma's Phase 1/2 study of oral fadraciclib in solid tumors and lymphomas
Cyclacel Pharmaceuticals (CYCC) announces dosing of the first patient in its multi-cohort Phase 1/2 study of oral fadraciclib in patients with advanced solid tumors. The Phase 1/2 registration-directed trial (CYC065-101)
Seekingalpha · 07/13 11:31
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing
Benzinga · 07/13 11:05
Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann's Virtual 2021 Healthcare Conference
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Ladenburg Thalmann's Virtua...
GlobeNewswire · 07/07 11:15
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 06/04 20:38
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 05/19 21:36
Buy These 2 Stocks Before They Double, Says Oppenheimer
The stock markets can sometimes be a study in paradoxes. Good and bad news will exist simultaneously, tugging in various directions, and short-term trends can shift in a single trading session. Start with two data points noted by Oppenheimer’s chief invest...
TipRanks · 05/18 00:30
BRIEF-Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results
reuters.com · 05/12 21:12
Cyclacel Pharmaceuticals EPS misses by $0.99
Cyclacel Pharmaceuticals (CYCC): Q1 GAAP EPS of -$1.48 misses by $0.99.As of March 31, 2021, cash and cash equivalents totaled $47.8 million, compared to $33.4 million as of December 31,
Seekingalpha · 05/12 20:28
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 05/12 12:57
Earnings Scheduled For May 12, 2021
  Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for its first quarter.
Benzinga · 05/12 08:22
Webull provides a variety of real-time CYCC stock news. You can receive the latest news about Cyclacel Pharms through multiple platforms. This information may help you make smarter investment decisions.
About CYCC
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.